Although larger patient cohorts are required to determine the potential of PD-1 expression as a biomarker, these data support the potential for clinical translation of our findings in MCAO models and show that PD-1 is differentially expressed on monocyte subtypes after stroke. This evidence concerns the gene PDCD1 and stroke disorder.